Trial Profile
Using Proton MRS to Predict Response of Vorinostat Treatment in Glioblastoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Vorinostat (Primary)
- Indications Glioblastoma
- Focus Pharmacodynamics; Therapeutic Use
- 14 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 10 Nov 2011 Planned End Date added to 1 May 2012 as reported by ClinicalTrials.gov.